CYCN

Company Overview — What Does Cyclerion Therapeutics, Inc. Do?

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Cyclerion Therapeutics, Inc. (CYCN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Peter M. Hecht and employs approximately 30 people. With a market capitalization of $24M, CYCN is one of the notable companies in the Healthcare sector.

Cyclerion Therapeutics, Inc. (CYCN) Stock Rating — Reduce (April 2026)

As of April 2026, Cyclerion Therapeutics, Inc. receives a Reduce rating with a composite score of 28.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CYCN ranks #2,706 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cyclerion Therapeutics, Inc. ranks #366 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CYCN Stock Price and 52-Week Range

Cyclerion Therapeutics, Inc. (CYCN) currently trades at $2.98. The stock lost $0.18 (5.7%) in the most recent trading session. The 52-week high for CYCN is $3.79, which means the stock is currently trading -21.4% from its annual peak. The 52-week low is $1.03, putting the stock 190.3% above its annual trough. Recent trading volume was 194K shares, suggesting relatively thin trading activity.

Is CYCN Overvalued or Undervalued? — Valuation Analysis

Cyclerion Therapeutics, Inc. (CYCN) carries a value factor score of 19/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.66x, versus the sector average of 2.75x. The price-to-sales ratio is 12.12x, compared to 1.66x for the average Healthcare stock.

At current multiples, Cyclerion Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cyclerion Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Cyclerion Therapeutics, Inc. (CYCN) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -38.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -34.6% versus the sector average of -33.1%.

On a margin basis, Cyclerion Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1073.3% (sector: -66.1%). Net profit margin stands at -649.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 351.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CYCN Debt, Balance Sheet, and Financial Health

Cyclerion Therapeutics, Inc. has a debt-to-equity ratio of 10.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.15x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $5M.

CYCN has a beta of 1.24, meaning it is more volatile than the broader market — a $10,000 investment in CYCN would be expected to move 23.7% more than the S&P 500 on any given day. The stability factor score for Cyclerion Therapeutics, Inc. is 15/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cyclerion Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cyclerion Therapeutics, Inc. reported revenue of $1M and earnings per share (EPS) of $-1.11. Net income for the quarter was $-3M. Gross margin was 100.0%. Operating income came in at $-5M.

In FY 2025, Cyclerion Therapeutics, Inc. reported revenue of $2M and earnings per share (EPS) of $-1.11. Net income for the quarter was $-4M. Revenue grew 3.7% year-over-year compared to FY 2024. Operating income came in at $-5M.

In Q3 2025, Cyclerion Therapeutics, Inc. reported revenue of $875,000 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-976,000. Revenue grew 351.0% year-over-year compared to Q3 2024. Operating income came in at $-1M.

In Q2 2025, Cyclerion Therapeutics, Inc. reported revenue of $93,000 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-324,000. Operating income came in at $-2M.

Over the past 8 quarters, Cyclerion Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $1M. Investors analyzing CYCN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CYCN Dividend Yield and Income Analysis

Cyclerion Therapeutics, Inc. (CYCN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CYCN Momentum and Technical Analysis Profile

Cyclerion Therapeutics, Inc. (CYCN) has a momentum factor score of 44/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

CYCN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cyclerion Therapeutics, Inc. (CYCN) ranks #366 out of 838 stocks based on the Blank Capital composite score. This places CYCN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CYCN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CYCN vs S&P 500 (SPY) comparison to assess how Cyclerion Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

CYCN Next Earnings Date

No upcoming earnings date has been announced for Cyclerion Therapeutics, Inc. (CYCN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CYCN? — Investment Thesis Summary

The quantitative profile for Cyclerion Therapeutics, Inc. suggests caution. The quality score of 18/100 flags below-average profitability. The value score of 19/100 indicates premium valuation. High volatility (stability score 15/100) increases portfolio risk.

In summary, Cyclerion Therapeutics, Inc. (CYCN) earns a Reduce rating with a composite score of 28.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CYCN stock.

Related Resources for CYCN Investors

Explore more research and tools: CYCN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CYCN head-to-head with peers: CYCN vs AZN, CYCN vs SLGL, CYCN vs VMD.